Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

3 Months Ended

Mar. 31, 2023

NONCONTROLLING INTEREST

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(1,447	)		$	(1,668	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(350	)		$	(584	)

		BioCorRx Pharmaceuticals, Inc.
Net loss		$	(2,276	)
Average Non-controlling interest percentage of profit/losses			24.2	%
Net loss attributable to the non-controlling interest		$	(551	)

Balance, December 31, 2022		$	(125,257	)
Net loss attributable to the non-controlling interest			(934	)
Balance, March 31, 2023		$	(126,191	)

Balance, December 31, 2021		$	(117,838	)
Net loss attributable to the non-controlling interest			(551	)
Balance, March 31, 2022		$	(118,389	)